---
title: "Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Cytotoxic chemotherapy"
description: "Formulary evidence on Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Cytotoxic chemotherapy. Topics: Platinum-based chemotherapy as first-line treatment, Chemotherapy responses without demonstrated survival benefit, Platinum plus fluorouracil versus methotrexate: randomized phase 3 trial, Cisplatin plus paclitaxel versus cisplatin plus fluorouracil: randomized phase 3 trial, and 4 further topics. 8 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description/cytotoxic-chemotherapy"
published: "2026-11-15T21:46:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Cytotoxic chemotherapy

<a id="heading-2.2.2.1.4"></a>

## 2.2.2.1.4 Cytotoxic Chemotherapy

<a id="topic-2.2.2.1.4-1"></a>

### Platinum-based chemotherapy as first-line treatment

> “Platinum-based chemotherapy is often used as first-line treatment for patients with metastatic or recurrent squamous cell carcinoma (SCC) of the head and neck.”

Source: [National Cancer Institute Oropharyngeal Cancer Treatment PDQ (2025)](https://www.cancer.gov/types/head-and-neck/hp/adult/oropharyngeal-treatment-pdq)

<a id="topic-2.2.2.1.4-2"></a>

### Chemotherapy responses without demonstrated survival benefit

> “Although chemotherapy has been shown to induce responses, no increase in survival has been demonstrated.”

Source: [National Cancer Institute Lip and Oral Cavity Cancer Treatment PDQ (2025)](https://www.cancer.gov/types/head-and-neck/hp/adult/lip-mouth-treatment-pdq)

<a id="topic-2.2.2.1.4-3"></a>

### Platinum plus fluorouracil versus methotrexate: randomized phase 3 trial

> “Two hundred seventy-seven patients diagnosed with SCC of the head and neck were randomized to one of three treatments”
> “The complete and partial response rates were 32% for cisplatin plus 5-FU, 21% for carboplatin plus 5-FU, and 10% for MTX.”
> “Median response durations and median survival times were similar for all three treatment groups.”
> “We conclude that combination chemotherapy resulted in improved response rates but was associated with an increased toxicity and no improvement in overall survival.”

Source: [Forastiere et al. (1992)](https://pubmed.ncbi.nlm.nih.gov/1634913/)

<a id="topic-2.2.2.1.4-4"></a>

### Cisplatin plus paclitaxel versus cisplatin plus fluorouracil: randomized phase 3 trial

> “Two hundred eighteen patients with locally advanced, recurrent, or metastatic disease were randomly assigned to CF (cisplatin 100 mg/m2 day 1 and fluorouracil 1,000 mg/m2/24 hours by continuous intravenous infusion day 1 through 4) or CP (cisplatin 75 mg/m2 day 1 and paclitaxel 175 mg/m2 over 3 hours on day 1).”
> “Estimated median survival was 8.7 months in the CF group and 8.1 month in the CP group. Objective response rate (complete response plus partial response) was 27% in the CF group and 26% in the CP group.”
> “A total of 12 deaths occurred (CF, seven; CP, five) during treatment”

Source: [Gibson et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/15908667/)

<a id="topic-2.2.2.1.4-5"></a>

### Taxane in place of fluorouracil with pembrolizumab: single-arm phase 4 trial

> “Patients received pembrolizumab 200 mg intravenously once every 3 weeks for ≤35 cycles and carboplatin AUC 5 mg/mL/min intravenously once every 3 weeks for ≤6 cycles and investigator's choice of paclitaxel 100 mg/m2 on days 1 and 8 or 175 mg/m2 on day 1, intravenously once every 3 weeks.”
> “At this final analysis, 49 (49%) of 101 patients had an objective response (95% CI, 38.4 to 58.7), including seven patients (7%) with a confirmed complete response.”
> “Of the 101 treated patients, grade 3-5 and serious treatment-related adverse events occurred in 76 (75%) and 27 (27%), respectively.”

Source: [Dzienis et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11361359/)

<a id="topic-2.2.2.1.4-6"></a>

### Pembrolizumab plus platinum plus taxane: United States real-world outcomes

> “the toxicity of 5-FU has motivated the study of alternate combinations that replace 5-FU with a taxane.”
> “The study population comprised 83 individuals (80.7% male) with a median age of 64 years.”
> “The median (95% CI) rwOS was 14.9 (8.8-23.3) months, rwToT was 5.3 (4.0-8.2) months”

Source: [Black et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10881782/)

<a id="topic-2.2.2.1.4-7"></a>

### Single-agent methotrexate, docetaxel, or cetuximab as the comparator after platinum

> “Two phase III trials, KEYNOTE-040 and CheckMate 141, evaluated anti–PD-1 therapies, pembrolizumab (KEYNOTE-040) and nivolumab (CheckMate 141), compared to standard-of-care single-agent therapy (methotrexate, docetaxel, or cetuximab).”

Source: [Yilmaz et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.22.02328)

<a id="topic-2.2.2.1.4-8"></a>

### Single-agent standard therapy after platinum: response and survival in a phase 3 control arm

> “The response rate was 13.3% in the nivolumab group versus 5.8% in the standard-therapy group.”
> “Treatment-related adverse events of grade 3 or 4 occurred in 13.1% of the patients in the nivolumab group versus 35.1% of those in the standard-therapy group.”

Source: [Ferris et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5564292/)

## Related pages
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Terms and abbreviations](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations.md)
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product information and disease description](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Clinical evidence](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic information and modeling report](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: References](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references.md)
